NO reasons are enough
BioMarin Pharmaceutical Inc.’s Kuvan is a dissolvable tablet formulation of tetrahydrobiopterin, an enzyme cofactor that metabolizes phenylalanine, the overabundant amino acid in phenylketonuria. Based on this mechanism, BMRN has taken the product through Phase III testing in PKU and expects to submit an NDA for the indication next quarter.
Tetrahydrobiopterin also promotes the synthesis